Picture [iito] Made Without Love 650x80px
Organisation › Details

Virometix AG

Virometix AG is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. In an increasingly global world, there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases, including cancer. Rational molecular design, chemical synthesis and Virometix' proprietary “Synthetic Virus-Like Particle” platform technology allow for the rapid production and optimization of vaccine candidates with the potential to demonstrate superior properties in terms of safety, efficacy and stability. *


Period Start 2020-07-09 existent
Products Industry immunotherapy
  Industry 2 Synthetic Virus-Like Particle technology (SVLP technology)
Persons Person Casse, Anna (Alacrita 201706– Managing Partner before BioVault + Ariad Europe + Novartis + Arthur D Little)
  Person 2 Navid, Sasan (Virometix 202007 CFO before Amgen + Ernst & Young)
  Street 14 Wagistr.
  City 8952 Schlieren ZH
  Tel +41-43-433-8660
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: Anergis S.A.. (7/9/20). "Press Release: Anergis and Virometix Announce Research Collaboration to Use Synthetic Virus-Like Particles for Ultra-Fast Allergy Immunotherapy". Epalinges.
Record changed: 2020-07-13


Picture [iito] Made Without Love 650x80px

More documents for Virometix AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top